Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions

Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average survival of only 13 months. Identification of novel predictive and actionable biomarkers in the homologous recombination repair (HRR) pathway in up to a quarter of patients with mCRPC has led to the approval of tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Rodney J., Mehta, Anurag, Macedo, Gabriel S., Borisov, Pavel S., Kanesvaran, Ravindran, El Metnawy, Wafaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351605/
https://www.ncbi.nlm.nih.gov/pubmed/34381565
http://dx.doi.org/10.18632/oncotarget.28015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351605/
https://www.ncbi.nlm.nih.gov/pubmed/34381565
http://dx.doi.org/10.18632/oncotarget.28015

Ejemplares similares